Acquired resistance to immunotherapy in MMR-D pancreatic cancer

Keyphrases

• Acquired Resistance 100%
• Pancreatic Cancer 100%
• Mismatch Repair 100%
• Resistance to Immunotherapy 100%
• Tumor 40%
• Progressive Disease 40%
• Immune Profiling 40%
• Disease Progression 20%
• Clinical Trials 20%
• Metastasis 20%
• Tumor Cells 20%
• Next-generation Sequencing 20%
• Disease Burden 20%
• Response to Therapy 20%
• CD8+ T Cells 20%
• Pancreas 20%
• Partial Response 20%
• Immune Cells 20%
• Older Women 20%
• Stable Disease 20%
• Endometrium 20%
• Appendectomy 20%
• Drug-resistant Tumor 20%
• Treatment-resistant 20%
• Genomic Profiling 20%
• Tumor Marker 20%
• Cystic Mass 20%
• Carbohydrate Antigen 19-9 (CA19-9) 20%
• Total Hysterectomy 20%
• FOLFIRINOX 20%
• Localized Treatment 20%
• Immune Checkpoint Therapy 20%
• Omentectomy 20%
• Left Ovary 20%
• Modified Response Evaluation Criteria in Solid Tumors (mRECIST) 20%
• PD-L1 Expression 20%
• Anti-PD-L1 Antibody 20%
• Stereotactic Body Radiation 20%
• FOLFIRI 20%
• Pelvic Lymphadenopathy 20%
• PD-1 Blockade Therapy 20%
• Oligoprogression 20%
• RNF43 20%
• Programmed Cell Death Protein 1 (PD-1) 20%
• IDO1 Inhibitor 20%
• KRAS G12D 20%
• Immune Cell Infiltration 20%
• Bilateral Salpingo-oophorectomy 20%

Medicine and Dentistry

• Immunotherapy 100%
• Pancreas Cancer 100%
• Neoplasm 33%
• Immunocompetent Cell 33%
• Programmed Death-Ligand 1 33%
• Progressive Disease 33%
• Clinical Trial 16%
• Tumor Cell 16%
• Hysterectomy 16%
• Disease Burden 16%
• Pelvis 16%
• Lymphadenopathy 16%
• Cancer Treatment 16%
• Cytotoxic T-Cell 16%
• Next Generation Sequencing 16%
• Whole Body Radiation 16%
• Endometrium 16%
• Appendectomy 16%
• Salpingooophorectomy 16%
• Case Presentation 16%
• Tumor Marker 16%
• CA19-9 16%
• Omentectomy 16%
• FOLFIRI 16%
• Diseases 16%
• Genetics 16%